53
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated

      research-article
      1 , 2 , , 1 , 6 , 1 , 1 , 1 , 2 , 1 , 2 , 1 , 1 , 2 , 1 , 1 , 2 , 7 , 8 , 8 , 8 , 4 , 8 , 1 , 2 , 9 , 1 , 2 , 10 , 10 , 11 , 11 , 11 , 10 , 12 , 5 , 1 , 4 , 5 , 1 , 3 , 5 , 6 , 1 , 2 , 5 ,
      The Journal of Experimental Medicine
      The Rockefeller University Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Many HIV-1 envelope-reactive antibodies shortly after HIV-1 transmission may arise from crow-reactive memory B cells previously stimulated by non-HIV-1 host or microbial antigens

          Abstract

          The initial antibody response to HIV-1 is targeted to envelope (Env) gp41, and is nonneutralizing and ineffective in controlling viremia. To understand the origins and characteristics of gp41-binding antibodies produced shortly after HIV-1 transmission, we isolated and studied gp41-reactive plasma cells from subjects acutely infected with HIV-1. The frequencies of somatic mutations were relatively high in these gp41-reactive antibodies. Reverted unmutated ancestors of gp41-reactive antibodies derived from subjects acutely infected with HIV-1 frequently did not react with autologous HIV-1 Env; however, these antibodies were polyreactive and frequently bound to host or bacterial antigens. In one large clonal lineage of gp41-reactive antibodies, reactivity to HIV-1 Env was acquired only after somatic mutations. Polyreactive gp41-binding antibodies were also isolated from uninfected individuals. These data suggest that the majority of gp41-binding antibodies produced after acute HIV-1 infection are cross-reactive responses generated by stimulating memory B cells that have previously been activated by non–HIV-1 antigens.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: not found
          • Article: not found

          Identification of common molecular subsequences.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Getting started with yeast.

            F. Sherman (1991)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The immune response during acute HIV-1 infection: clues for vaccine development

              Key Points The early virological factors in HIV-1 infection, including transmission and the nature of the founder virus, can affect the time course of viraemia through the early peak to set point. The identification of patients within the first few weeks of HIV-1 infection has provided early evidence of immune system damage, including massive apoptosis of CD4+ T cells, which is associated with the presence of apoptotic microparticles and TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) in the blood, and damage to germinal centres in mucosal lymphoid tissues. The first innate immune responses include the appearance of acute-phase proteins, early cytokine storm and activation of natural killer (NK) cells. An innate immune response to HIV-1 can be damaging, however, as it can draw susceptible T cells to the infection foci. The first T cell response controls the founder virus by killing infected T cells. However, the T cell response also selects mutational changes in the founder virus, allowing immune evasion. The first B cell response consists of early immune complexes, followed by non-neutralizing antibodies against the founder virus and then the slow development of broadly acting neutralizing antibodies. Development of vaccines that rapidly induce broadly acting neutralizing antibodies might be beneficial in preventing HIV infection. Understanding the early events and immune responses is crucial to devising vaccine strategies that can improve the weak protection offered by current HIV vaccines that are being trialled, such as the RV144 (Thai) efficacy trial.
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                24 October 2011
                : 208
                : 11
                : 2237-2249
                Affiliations
                [1 ]Duke Human Vaccine Institute , [2 ]Department of Medicine , [3 ]Department of Pediatrics , [4 ]Department of Surgery , [5 ]Department of Immunology , and [6 ]Center for Computational Immunology, Duke University School of Medicine, Durham, NC 27710
                [7 ]The Aaron Diamond AIDS Research Center, New York, NY 10016
                [8 ]University of Alabama-Birmingham, Birmingham, AL 35294
                [9 ]University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
                [10 ]Department of Pathology, Stanford School of Medicine, Stanford, CA 94305
                [11 ]454 Life Sciences, Branford, CT 06405
                [12 ]GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
                Author notes
                CORRESPONDENCE Hua-Xin Liao: hliao@ 123456duke.edu OR Barton F. Haynes: hayne002@ 123456mc.duke.edu

                X. Chen, S. Munshaw, G. Tomaras, M.A. Moody, and T.B. Kepler contributed equally to this paper.

                Article
                20110363
                10.1084/jem.20110363
                3201211
                21987658
                72be03dc-25bc-41f9-97a3-04b83cbe9bb3
                © 2011 Liao et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

                History
                : 16 February 2011
                : 31 August 2011
                Categories
                Article

                Medicine
                Medicine

                Comments

                Comment on this article